Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals Board of Directors
FOR IMMEDIATE RELEASE:
LEXINGTON, MA., July 12, 2016 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Jack A. Khattar has been appointed to scPharmaceuticals’ Board of Directors.
Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA, a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe and the Middle East. He served as a director of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately-held pharmaceutical company. Mr. Khattar earned his degrees in marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
“At this time of transition from a development to a commercial focus at scPharmaceuticals, it is a privilege to have Jack Khattar join the board of directors,” said Pieter Muntendam, president, CEO and founder of scPharmaceuticals and a member of its board of directors. “Mr. Khattar is a successful CEO of a public pharmaceutical company and brings to the board broad and extensive commercial experience combined with a thorough understanding of all aspects of a pharmaceutical enterprise.”
“Using innovative delivery technology, scPharmaceuticals aims to reduce healthcare costs while improving patient care,” said Mr. Khattar. “The need to reduce cost of care while improving outcomes has never been greater and I look forward to working with scPharmaceuticals to advance the company and address an important societal need.”
scPharmaceuticals, based in Lexington, MA, is a privately held pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost.
For More Information:
Director Corporate Development
Telephone: (781) 301-6706